Cellectis (ALCLS.PA) Stock Price
Cellectis Price
Over the last 19 years Cellectis grew revenue by 10.5% annually, reaching 49.22 M USD. For Cellectis, the net margin of -74.7% is up versus -136.1% a few years ago. The consensus 12-month price target for Cellectis is 7.68 USD, about 124.2% above where the stock trades today. Of 13 analysts, 11 rate the stock a buy — an overall Buy consensus. The stock trades about 29% above its 52-week low.
Cellectis stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Cellectis over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Cellectis stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Cellectis's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Cellectis Price |
|---|---|
| 9/2/2026 | 3.42 USD |
| 9/1/2026 | 3.31 USD |
| 8/31/2026 | 3.40 USD |
| 8/28/2026 | 3.52 USD |
| 8/27/2026 | 3.52 USD |
| 8/26/2026 | 3.54 USD |
| 8/25/2026 | 3.43 USD |
| 8/24/2026 | 3.22 USD |
| 8/21/2026 | 3.35 USD |
| 8/20/2026 | 3.45 USD |
| 8/19/2026 | 3.20 USD |
| 8/18/2026 | 3.09 USD |
| 8/17/2026 | 3.18 USD |
| 8/14/2026 | 3.17 USD |
| 8/13/2026 | 3.24 USD |
| 8/12/2026 | 3.10 USD |
| 8/11/2026 | 2.93 USD |
| 8/10/2026 | 2.89 USD |
| 8/7/2026 | 2.81 USD |
| 8/6/2026 | 2.83 USD |
| 8/5/2026 | 2.90 USD |
| 8/4/2026 | 2.84 USD |
| 8/3/2026 | 2.83 USD |
| 7/31/2026 | 2.88 USD |
| 7/30/2026 | 2.93 USD |
| 7/29/2026 | 2.94 USD |
| 7/28/2026 | 2.93 USD |
| 7/27/2026 | 2.97 USD |
| 7/24/2026 | 3.02 USD |
| 7/23/2026 | 2.87 USD |
Cellectis Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Cellectis Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 56.00 | 33.00 | 21.00 | 22.00 | 59.00 | 38.00 | 25.00 | 9.00 | 49.00 | 77.00 | 61.00 | 122.00 | 51.00 | 79.00 | 159.00 | 224.00 |
| -9.68 | -41.07 | -36.36 | 4.76 | 168.18 | -35.59 | -34.21 | -64.00 | 444.44 | 57.14 | -20.78 | 100.00 | -58.20 | 54.90 | 101.27 | 40.88 |
| 33.93 | -39.39 | -157.14 | -168.18 | 22.03 | -71.05 | -72.00 | -333.33 | 6.12 | 6.12 | 6.12 | 6.12 | 6.12 | 6.12 | 6.12 | 6.12 |
| 19.00 | -13.00 | -33.00 | -37.00 | 13.00 | -27.00 | -18.00 | -30.00 | 3.00 | 4.71 | 3.73 | 7.47 | 3.12 | 4.84 | 9.73 | 13.71 |
| -67.00 | -92.00 | -105.00 | -123.00 | -42.00 | -103.00 | -89.00 | -97.00 | -59.00 | -68.00 | -77.00 | -55.00 | -170.00 | -97.00 | -55.00 | – |
| -119.64 | -278.79 | -500.00 | -559.09 | -71.19 | -271.05 | -356.00 | -1,077.78 | -120.41 | -88.31 | -126.23 | -45.08 | -333.33 | -122.78 | -34.59 | – |
| -67.00 | -99.00 | -78.00 | -102.00 | -81.00 | -114.00 | -106.00 | -101.00 | -36.00 | -69.00 | -74.00 | -55.00 | -114.00 | -94.00 | -56.00 | – |
| 204.55 | 47.76 | -21.21 | 30.77 | -20.59 | 40.74 | -7.02 | -4.72 | -64.36 | 91.67 | 7.25 | -25.68 | 107.27 | -17.54 | -40.43 | – |
| 35.27 | 35.69 | 40.77 | 42.44 | 42.50 | 44.82 | 45.55 | 57.01 | 90.57 | 90.57 | 90.57 | 90.57 | 90.57 | 90.57 | 90.57 | 90.57 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Cellectis generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Cellectis retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Cellectis's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Cellectis has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Cellectis's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Cellectis stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Cellectis Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Cellectis business model & stock analysis
Cellectis Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Cellectis historical P/E ratio, EBIT multiple, and P/S ratio
Cellectis annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Cellectis shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Cellectis forecasts and price targets in September 2026
Analyst Price Targets 2026Cellectis Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/7/2023 | Maintained | Outperform | 62 | |
| 8/6/2023 | Maintained | Market Outperform | – | |
| 4/4/2023 | Maintained | Buy | 48 | |
| 3/13/2023 | Maintained | Market OutperformOutperform | – | |
| 3/12/2023 | Maintained | Outperform | 62 | |
| 1/19/2023 | Maintained | Market OutperformOutperform | – | |
| 1/18/2023 | Maintained | Market Outperform | – | |
| 5/23/2022 | Maintained | Sell | 60 | |
| 5/17/2022 | Upgrade | NeutralOutperform | 62 | |
| 5/12/2022 | Maintained | Overweight | 57 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Cellectis Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/3/2022 | -0.56USD | - | 13.70 MUSD | - | 2022 Q3 |
| 8/4/2022 | -0.70USD | - | -USD | - | 2022 Q2 |
| 5/12/2022 | -0.66USD | - | 13.70 MUSD | - | 2022 Q1 |
| 3/3/2022 | -1.13USD | - | 11.77 MUSD | - | 2021 Q4 |
| 11/4/2021 | -0.57USD | - | 12.18 MUSD | - | 2021 Q3 |
| 8/5/2021 | -0.62USD | - | 12.18 MUSD | - | 2021 Q2 |
| 5/12/2016 | -0.44USD | - | 9.84 MUSD | - | 2016 Q1 |
| 3/14/2016 | -0.43USD | - | 9.64 MUSD | - | 2015 Q4 |
EESG©
Eulerpool ESG Scorecard© for the Cellectis stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Cellectis shareholder structure
| % | Name |
|---|---|
0.52026% | |
0.09385% | |
0.06073% | |
0.01087% | |
0.00000% | |
0.00000% |
Cellectis Beneficial Ownership Filings (SEC 13D/G)
Cellectis Executives and Management Board
19 members · avg. age 59 · 16 % women
Dr. Andre Choulika (60)
Chief Executive Officer, Co-Founder, Director · since 2000
937,539.00 USD
Management
Dr. David Sourdive (58)
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director · since 2000
Mr. Arthur Stril (36)
Chief Financial Officer and Chief Business Officer
Ms. Kyung Nam-Wortman (55)
Chief Human Resources Officer, Executive Vice President
Dr. Steven Doares (65)
Senior Vice President - US Manufacturing
Dr. Philippe Duchateau (62)
Chief Scientific Officer
Mr. Stephan Reynier (55)
Chief Regulatory and Pharmaceutical Compliance Officer · since 2022
Board of Directors
Dr. Jean-Pierre Garnier (77)
Non-Executive Independent Chairman of the Board
Dr. Rainer Boehm (64)
Non-Executive Independent Director
Mr. Axel-Sven Malkomes (58)
Non-Executive Independent Director
Mr. Pierre Bastid (70)
Non-Executive Independent Director
Dr. Donald Bergstrom (53)
Non-Executive Independent Director
Dr. Cecile Chartier (58)
Non-Executive Independent Director
Frequently asked questions about Cellectis
The business model of Cellectis SA is focused on developing innovative gene-edited therapies for various diseases. Cellectis utilizes its proprietary gene-editing technology known as TALEN® to enable precise modifications to the genetic code of cells. The company aims to commercialize its therapies through strategic collaborations and partnerships. By leveraging its expertise in gene editing, Cellectis aims to address significant unmet medical needs and improve patient outcomes. Through its cutting-edge technology, Cellectis strives to harness the potential of gene editing to revolutionize personalized medicine and advance the field of cellular therapies.
Cellectis SA is primarily active in the biotechnology industry.
The main competitors of Cellectis SA in the market include companies such as Editas Medicine, Intellia Therapeutics, and CRISPR Therapeutics.
Cellectis SA is a biopharmaceutical company specializing in the development of innovative immunotherapies for patients with cancer. Founded in 1999, Cellectis has since been at the forefront of gene editing and engineered cell-based therapies. The company heavily focuses on harnessing the potential of allogeneic CAR-T cells to revolutionize cancer treatment. Cellectis has a rich history of pioneering advancements in gene editing, with its proprietary technology, TALEN® being recognized worldwide. By leveraging its expertise in genome engineering, Cellectis aims to provide safer, more effective treatments for patients in need. With a strong commitment to research and development, Cellectis continues to make significant contributions to the field of immunotherapy.
Cellectis SA has achieved several significant milestones in its journey. Over the years, the company has made remarkable progress in the field of gene editing and cell therapy. One of its notable accomplishments is the successful development of its proprietary gene-editing technology known as TALEN®. This groundbreaking technology enables precise and efficient modification of genetic material, offering immense potential in various applications, including the treatment of genetic diseases and the creation of gene-edited cell therapies. Additionally, Cellectis SA has also achieved noteworthy partnerships and collaborations within the pharmaceutical and biotech industries, further solidifying its position as a leader in the field. These milestones exemplify the company's commitment to advancing cutting-edge genetic engineering solutions.
Cellectis SA is primarily present in various countries and regions across the globe. The company has a strong presence in the United States, where it has established multiple research and development facilities. Cellectis SA also has significant operations in Europe, including France and Germany, where it conducts various specialized activities related to gene editing and cell therapy. Additionally, the company has expanded its reach into Asia, particularly in Japan, through collaborations and strategic partnerships. With its global footprint, Cellectis SA is well-positioned to leverage its innovative technologies and solutions in the field of gene editing and cell therapy across different markets.
Cellectis SA represents the values of innovation, collaboration, and integrity. The company's corporate philosophy revolves around advancing the field of precision medicine through the development of gene-edited cell therapies. Cellectis SA is committed to driving scientific advancements to enhance patient outcomes and improve quality of life. By leveraging its expertise in gene editing and genome engineering, the company aims to harness the power of the human immune system to treat various diseases, including cancer. Through continuous research and development, Cellectis SA is dedicated to transforming the future of healthcare and making a positive impact on patients' lives.
Analysts currently set an average price target of 7.68 USD for the Cellectis stock (median: 7.68 USD), implying +124.7 % versus the latest price. The consensus is based on 13 analyst ratings.
13 analysts currently rate the Cellectis stock: 11 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Cellectis to generate revenue of 61.03 M USD and earnings per share of -0.82 USD.
Converted at the current exchange rate, the Cellectis share trades at 2.95 EUR (3.42 USD).
The Cellectis share (ALCLS.PA) is listed on 7 stock exchanges, including: Frankfurt (ZVA.F), München (ZVA.MU), Düsseldorf (ZVA.DU), London (0WA2.L), Paris (ALCLS.PA).
Cellectis SA is a leading biotechnology company focused on developing innovative CAR-T cell therapies for patients with cancer and other serious diseases. The company is headquartered in Paris, France, and has offices in the US and Singapore. Cellectis SA's business model is based on three different divisions: clinical development of CAR-T cell therapies, delivery of solutions for genetic cell editing, and development of agricultural products through genome editing. In the field of clinical development of CAR-T cell therapies, Cellectis SA has developed a wide range of products targeting different types of cancer. The company's products include UCART19, UCART22, UCART123, and UCARTCS1, all of which are based on genetically modified T cells programmed to recognize and destroy cancer cells. Additionally, Cellectis SA is involved in the delivery of solutions for genetic cell editing. The company offers a wide range of technologies including Transcription Activator-Like Effector Nucleases (TALEN) and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 technology. These technologies allow researchers to make targeted changes to cell genomes for the treatment of diseases or improvement of agricultural yields. Furthermore, Cellectis SA has a division focused on the development of agricultural products through genome editing. The company utilizes its technologies to enhance plants and livestock and achieve higher yields. It has also formed a partnership with Monsanto. Overall, Cellectis SA is dedicated to developing innovative solutions in various areas including clinical development of CAR-T cell therapies, genetic cell editing, and improvement of agricultural products. The company has a broad portfolio of products and technologies that enable it to operate in diverse fields. Additionally, it has a strong research and development department that continuously improves its products and technologies and develops new solutions. Thanks to its innovative solutions, Cellectis SA has established a strong position in the biotechnology industry in recent years. The company has a wide range of customers and partners around the world, and its products and technologies are utilized by many researchers and scientists globally. In conclusion, Cellectis SA's business model is focused on developing innovative solutions in various areas, and the company has a wide range of products and technologies that enable it to operate in diverse fields.
The expected revenue of Cellectis is 61.03 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Cellectis is -74.08 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Cellectis is currently -4.19. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cellectis stock.
The price-to-sales ratio (P/S) of Cellectis is currently 5.08. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cellectis stock.
The Eulerpool Quality Score for Cellectis is 4/10.
The ISIN of Cellectis is FR0010425595. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Cellectis is A0MKPR. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Cellectis is ALCLS.PA. The ticker symbol is used to trade Cellectis shares on the stock exchange.
Cellectis paid dividends every year for the past 0 years.
Cellectis is assigned to the 'Health' sector.
The dividends of Cellectis are distributed in USD.
Cellectis stock
Cellectis Peer Group
Cellectis Ticker
Cellectis FIGI
All fundamentals and in-depth analysis of Cellectis
Our stock analysis for Cellectis stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cellectis. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.